Nykode Therapeutics makes $45 private placement
Norway’s clinical-stage biopharmaceutical company Nykode Therapeutics (Euronext Growth (Oslo): VACC) today announced that its private placement has been successfully placed, raising around 505 million Norwegian kroner (~$45 million) in gross proceeds through the allocation of 29,549,400 new shares at a subscription price of 17.10 kroner per share.
The private placement was multiple times oversubscribed and saw significant international investor participation, said Nykode. In early trading of the shares on the Euronext, they gained 2.5% to 1.67 euros.
Vaccibody, a Norway-based pioneer in the neoantigen cancer vaccine space, in 2019 changed its name to Nykode Therapeutics, and at the same time entered into a license and collaboration agreement with US company, Regeneron (Nasdaq: REGN), to develop vaccines against cancer and infectious diseases. The legacy company also entered into a collaboration with Roche’s (ROG: SIX) Genentech unit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze